The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
Jain Foundation Inc.
9725 Third Avenue NE
Seattle, WA 98115
The Jain Foundation Inc. (JFI) is a non-profit organization whose mission is to initiate and accelerate research essential to developing a therapy or cure for Type 2B Limb Girdle Muscular Dystrophy (LGMD2B)/Miyoshi Myopathy, and to provide diagnostic tools worldwide for addressing this disease. Onset of LGMD2B is usually during the juvenile years. Most individuals have normal mobility during childhood. Muscle weakness affects muscles of both the pelvic and shoulder area, but usually progresses very slowly. Wasting (atrophy) of the calf muscle and an inability to walk on tiptoes may be seen early in the disease progression. In rare cases, temporary (transient) overgrowth of the calf muscle, painful swelling of the calf, and early development of contractures may occur. LGMD2B is caused by mutations of a gene that also causes Miyoshi myopathy, a rare muscle disorder characterized by weakness of the distal muscles of the legs and arms. The Jain Foundation targets specifically LGMD2B/Miyoshi Myopathy by providing the following programs and services: funding research projects in key pathways towards a cure; funding, tracking and organizing clinical trials; providing financial and logistic support to promising drug candidates to accelerate them to clinical trials; giving advice about gene sequencing options; helping to find appropriate experts on this disease (both scientific and clinical) in the patient's country or area; providing information about ongoing clinical trials that may be relevant to the patient.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and that credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions are strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.